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Summary The extracellular pH (pHe) of solid tumours is often lower than in normal tissues, and this may influence the uptake and/or activity
of anti-cancer drugs. The cytotoxicity of mitoxantrone, paclitaxel and topotecan was therefore assessed at low pHe and after manipulation of
intracellular pH (pH) in murine EMT6 and in human MGH-U1 cells. The cytotoxic efficacy of all three agents was reduced at PHe 6.5 as
compared with PHe 7.4. The ionophore nigericin and inhibitors of membrane-based ion exchange mechanisms that regulate pH, (5-[N-ethyl-
N-isopropyl] amiloride, EIPA; 4,4-diisothiocyanstilbene 2,2-disulphonic acid, DIDS) were used to cause intracellular acidification. Combined
use of the cytostatic drugs with pH, modifiers reduced their cytotoxicity under both physiological and low-pHe conditions. The uptake into cells
of mitoxantrone (a weak base) was inhibited atPHe 6.5 as compared with pHe 7.4, and smaller effects of low PHe to inhibit uptake of topotecan
were also observed. DNA analysis of cell cycle distribution revealed that intracellular acidification, as observed during incubation at low pHe
and/or using pHi modifiers, resulted in accumulation of cells in G, phase, where they may be more resistant to these drugs. Reduced uptake
of weak bases (mitoxantrone) at low PHe and altered cell cycle kinetics upon acidification are the postulated causes of reduced cytotoxicity of
the agents investigated.
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Solid tumours are known to develop a microenvironment in which
the pH (pHe) is often lower than in normal tissues (Wike-Hooley et
al, 1984; Vaupel et al, 1989). In contrast, intracellular pH (pHi) as
assessed by 3'P magnetic resonance spectroscopy is usually main-
tained at physiological levels in both tumours and normal tissues,
as is expected for the survival of constituent cells, although
severely hypoxic tumours may have lower pH, values (Vaupel et
al, 1994). The maintenance of physiological values ofpHi in the
face of an acidic PHe depends on the buffering capacity ofthe cell
and on membrane-based ion exchangers, the Na+/H+ antiport and
the Na+-dependent HCO3-/Cl- exchange mechanism (Madshus et
al, 1988; Boyer et al, 1992). These exchangers may be inhibited
respectively by amiloride and its analogues (e.g. 5-[N-ethyl-N-
isopropyl] amiloride, EIPA) and by stilbene derivatives (e.g.
4,4- diisothiocyanstilbene 2,2-disulphonic acid, DIDS).
The presence of an H+ gradient across the membrane oftumour
cells has implications for chemotherapy. Acidic values ofPHe are
likely to facilitate the uptake of weak acids, such as melphalan
(Skarsgaard et al, 1995), as more of the compound will be in the
uncharged form at low values of PHe (Karuri et al, 1993). In
contrast, extracellular acidity will inhibit the uptake ofweak bases
such as doxorubicin (Alabaster et al, 1989). These effects may be
modified by agents that dissipate the pH gradient across the
membrane (e.g. the K+/H+ exchange ionophore, nigericin) and/or
by inhibition of the membrane-based exchange mechanisms that
regulatepH, (Parkins et al, 1996).
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Paclitaxel, mitoxantrone and topotecan (9-dimethyl-amino-
methyl-20-hydroxy-camptothecin) are anti-cancer drugs that are
gaining increasing importance in the therapy of solid tumours. In
the present paper we assess the influence of acidic PHe on their
uptake and/or activity, and the influence on their cytotoxicity of
agents that modify the pH gradient across the cell membrane.
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Figure 1 Intracellular pH (pH,) measurement using BCECF AM. MGH-U1
and EMT6 cells were incubated in the presence or absence of EIPA (E) and
DIDS (D) and/or nigericin (N) for 3 h at pH 7.4 (O) and pHe 6.5 (-). Columns
are mean values, error bars are standard deviations
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MATERIALS AND METHODS
Reagents
Nigericin, DIDS and the buffers Hepes and Bis-Tris were
purchased from Siama (St Louis, MO, USA). EIPA was purchased
from Research Biochemical International (Natick, MA, USA).
DIDS was dissolved in 50% DMSO, EIPA was dissolved in 10%
DMSO and nigericin was dissolved in absolute ethanol. In cell
culture experiments, the final concentration of each solvent was
< 0.1%. Mitoxantrone (Novantrone) was purchased as the formu-
lation for clinical use from Wyeth-Ayerst Canada (Montreal, PQ,
Canada), paclitaxel (Taxol) was purchased as the formulation for
clinical use from Bristol-Myers Squibb Canada (Montreal, PQ,
Canada), and topotecan was provided by SmithKline Beecham
Pharmaceuticals (King of Prussia, PA, USA). BCECF-AM was
purchased from Molecular Probes (Eugene, OR, USA).
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Cells
Experiments were performed with murine EMT6 cells (obtained
originally from Dr R Sutherland, University of Rochester, NY,
USA) and the human bladder carcinoma cell line MGH-Ul
(obtained originally from Dr G Prout, Massachusetts General
Hospital, Boston, MA, USA). Cells were maintained in u-MEM,
supplemented with 10% fetal bovine serum (FBS) and 0.1 mg ml
kanamycin and were passaged routinely twice a week. Cells were
discarded every 3 months and reestablished from frozen stock.
They were tested and found to be free of mycoplasma. To prepare
medium at different values of pH, 20 mM Hepes or Bis-Tris were
added to regular o-MEM and adjusted with I N sodium hydroxide
or HCI to pH 7.4 or 6.5 respectively. After a 24-h period in the
carbon dioxide incubator, the pH of the medium was adjusted to
the desired values.
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Figure 2 Uptake of mitoxantrone (MX) into EMT6 cells (A), topotecan (TOPO) into EMT6 cells (C), MX into MGH-U1 cells (B) and TOPO into MGH-U1 cells
(D). Cells were incubated in the presence of EIPA (E) and DIDS (D) and/or nigericin (N) for 3 h at pH 7.4(LE) and pH, 6.5 (-). Columns are mean values, error
bars are standard deviations
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Figure 3 Cytotoxicity of mitoxantrone, paclitaxel and topotecan atpH. 7.4
and 6.5. EMT6 cells were incubated with different concentrations of the
drugs atpHe 7.4 (0) and 6.5 (@) for 24 h. Points represent mean values,
error bars are standard deviations (when not shown, they are less than the
height of the symbols)
Measurement ofpH,
Exponentially growing EMT6 and MGH-U1 cells were detached
using 0.025% trypsin and 0.01% EDTA, washed and resuspended
in x-MEM, and plated on 24 mm x 6 mm glass coverslips (5 x 104
cells per coverslip). The coverslips were placed in 60-mm Petri
dishes (Nunc, Kamstrup, Denmark) with 5 ml of a-MEM. After
24 h, the medium was replaced with a-MEM atpH 7.4 or 6.5, with
or without EIPA (10 gM), DIDS (100 gM) and nigericin (0.3 gM).
Topotecan (gM)
Figure 4 Cytotoxicity of mitoxantrone, paclitaxel and topotecan at pHe 7.4
and 6.5. MGH-U1 cells were incubated with different concentrations of the
drugs at pHe 7.4 (0) and 6.5 (@) for 24 h. Points represent mean values,
error bars are standard deviations (when not shown, they are less than the
height of the symbols)
Thirty minutes before pHi measurement, 2 ig ml-' BCECF-AM
was added to the samples. After dye loading, the coverslips were
rinsed in phosphate-buffered saline (PBS) and the ratio ofintracel-
lular fluorescence emission at 525 nm after excitation at 495 nm
(pHi sensitive) to that at 440 nm(pHi insensitive) was determined.
A fluorescence calibration curve for different pHi values was
established using the ionophore nigericin and solutions containing
140 mm K+, as described elsewhere (Boyer et al, 1992).
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Figure 5 Influence of pH. modifiers on cytotoxicity of mitoxantrone (MX) (A),
paclitaxel (PX) (B) and topotecan (TOPO) (C) under physiological and low
pH0 conditions. EMT6 cells were incubated for 24 h at pH* 7.4 (Oi) and pH0
6.5 (e) in the presence of mitoxantrone [10 nM], paclitaxei[100 nMJ and
topotecan [3 l.M], with or without EIPA [E: 10 RM], DIDS [D: 100 jiM] and/or
nigericin [N: 0.3 jiM]. Columns are mean values, error bars are standard
deviations
Drug uptake
The uptake of mitoxantrone and topotecan into cells was assessed
by using flow cytometry. Exponentially growing EMT6 and
MGH-Ul cells were detached using 0.025% trypsin and 0.01%
EDTA, washed and resuspended in a-MEM, at pH 7.4 or 6.5. Cell
number was adjusted to 1 x 106 cells ml-'. Drugs or solvents were
added, and cells were incubated at 37°C. Samples were analysed
using a Coulter Epics Elite flow cytometer (Miami, FL, USA). For
mitoxantrone, a He/Ne laser was used for excitation at 633 nm;
fluorescence was collected at 675 nm, with a 40-nm bandpass
filter. For topotecan, after UV excitation at 325 nm, emission was
measured at 525 nm, using a 20-nm bandpass filter. Cellular
debris was excluded by forward scatter gating. A total of 5 x 103
events per sample were collected. Drug uptake was expressed as
the mean fluorescence ratio (MFR), using the formula MFR=f!/fc,
wherefS is the mean fluorescence of treated cells andfc is the mean
fluorescence of control cells. Experiments were repeated at least
three times.
Cell survival
Exponentially growing EMT6 or MGH-Ul cells were detached
using 0.025% trypsin and 0.01% EDTA, washed and resuspended
in a-MEM and supplemented with 10% FBS. Cells at a concentra-
tion of 0.5-1 x 10's cells were plated in 60-mm Petri dishes and
incubated overnight in the carbon dioxide incubator (95% air,
5% carbon dioxide). After 24 h, the medium was aspirated and
replaced with 5 ml of a-MEM, buffered to pH 7.4 or 6.5,
containing either the drugs or solvents. After 24 h of incubation,
the drug-containing medium was aspirated, cells were washed
with PBS (3 x 5 ml), detached using 0.025% trypsin and 0.01%
EDTA, washed and resuspended in a-MEM. The cells were
counted, serially diluted and plated in triplicate in 60-mm Petri
dishes. After approximately 8 days' incubation, colonies were
stained with methylene blue and counted. All experiments were
performed three times. The pH of media was determined before
and after cell incubation. Dishes in which there was variation of
more than 0.1 pH unit from the preset pH values were discarded.
DNA analysis
Because the activity ofdrugs depends on cell cycle phase distribu-
tion, we analysed the DNA content ofcells under different condi-
tions using flow cytometry. For DNA analysis, samples were
prepared as for cell survival experiments. After a 24-h incubation
at pH 7.4 or pH 6.5, in the presence of EIPA (10 gM), DIDS
(100 ,UM) and/or nigericin (0.3 gM) or under control conditions,
exponentially growing cells were washed with PBS (3 x 5 ml),
and detached using 0.025% trypsin and 0.01% EDTA. After
centrifugation, cell pellets were resuspended in 1 ml of PBS
containing 50 gg ml-1 propidium iodide and 0.1% Triton X-100,
and incubated for30 min at 370C. Afterexcitation at488 nm, fluo-
rescence from 5 x 103 events per sample was collected at 640 nm.
DNA histogram analysis was peformed using the Phoenix Flow
Systems Multicycle software (San Diego, CA, USA). Experiments
were repeated three or four times.
RESULTS
Measurement of pH,
As shown in Figure 1, only the combined presence ofEIPA, DIDS
and nigericin decreased the pHi significantly in either cell line
when exposed topHe 7.4. At PHe 6.5, acidification occurred in the
absence of modifying agents in MGH-Ul but not in EMT6 cells;
addition of EIPA and DIDS acidified EMT6 cells, but led to no
further acidification of MGH-Ul cells compared with control.
When nigericin was added to MGH-Ul cells exposed at PHe 6.5,
either alone orin combination withEIPA and DIDS, pH. decreased
to about pH 6.6; nigericin was less effective when used alone for
EMT6 cells, but the combination of three agents acidified EMT6
cells to pHi 6.4 after 3 h of incubation. This decrease was time
dependent (data not shown).
Uptake of mitoxantrone and topotecan
The uptake of mitoxantrone into cells, as shown in Figure 2A and
B, was approximately twofold higher at PHe 7.4 than at PHe 6.5
(EMT6 cells P < 0.01, MGH-Ul cells P < 0.05). A small increase
in cellular accumulation of mitoxantrone at both pHe values was
observed when the Na+/H+ antiport and the Na+-dependent
HCO3-/Cl- exchanger were blocked with 10 ,UM EIPA and 100 gM
DIDS respectively. When cells were incubated in the presence of
nigericin, with or withoutEIPA andDIDS, uptake ofmitoxantrone
was slightly greater at PHe 7.4, and similar at pHe 6.5, to uptake
under control conditions.
The uptake of topotecan into EMT6 and MGH-Ul cells is
shown in Figure 2C and D. Treatment with EIPA and DIDS in
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combination did not alter the uptake oftopotecan atpHe 7.4 or6.5.
Nigericin increased significantly the uptake oftopotecan atPHe 7.4
but only minimally at pHe 6.5. When all threepHi modifiers were
added, drug uptake decreased to control levels at PHe 7.4 and to
values lower than under control conditions atPHe 6.5.
Cell survival experiments
Greater cytotoxicity for each drug was observed at PHe 7.4 than at
PHe 6.5 in both cell lines investigated (Figures 3 and 4). The
effects of modifiers ofpH, on cytotoxicity are shown for EMT6
cells in Figure 5. Similar results were found for MGH-U1 cells
(data not shown).
The drug concentration equivalent to LD90 was chosen for
experiments usingpHi modifiers, as it should be possible to deter-
mine both increases or decreases in cytotoxicity within one exper-
iment. The pHi modifiers alone (EIPA 10 gM, DIDS 100 gM and
nigericin 0.3 gM) did not exert significant cytotoxicity. Only the
combination of all three agents at PHe 6.5 caused significant cell
kill, as has been described previously (Rotin et al, 1987). The cyto-
toxicity ofmitoxantrone was reduced substantially in the presence
of EIPA and DIDS. When incubated with nigericin, the cytotoxi-
city of mitoxantrone was decreased both at PH. 7.4 and 6.5 by a
factor of 2. When all three pH, modifiers were incubated with
mitoxantrone, the observed cytotoxic effects were not different to
the pH. modifiers used alone. The results obtained with paclitaxel
and topotecan are very similarto mitoxantrone, showing decreased
cytotoxic potency of the drugs when combined with EIPA and
DIDS or nigericin (Figure 5).
DNA analysis
The distributions of cells in different phases of the cell cycle after
incubation for 24 h at PHe 7.4 or 6.5 in the presence or absence of
modifiers of pHp, are shown in the Table. At pHe7.4, untreated
exponentially growing EMT6 and MGH-U1 cells show a nearly
equal distribution of cells inG, and S/G2 cell cycle phases. In the
presence ofeithernigericin or EIPA and DIDS, the numberofcells
in GI phase increases to about 60%. Combination of all three pHi
modifiers increases the number ofEMT6 and MGH-Ul cells inG,
phase to approximately 72% and 80% respectively. The number of
cells in G2 phase decreases in the presence ofnigericin to approxi-
mately halfofthe number ofcells treated with EIPA and DIDS, or
control. At PH. 6.5, untreated EMT6 cells cells have approximately
54% of cells in G, phase, increasing to approximately 80% when
the cells were incubated in the presence ofnigericin. Conditions of
PHe 6.5, with or withoutpHi modulators, had a similareffect on the
cellcycle distribution ofMGH-U1 cells (Table).
DISCUSSION
The present study addresses two questions: (a) whether low PHe
(6.5), as can be found in acidic regions ofmany solidtumours, influ-
ences the cytotoxicity of mitoxantrone, paclitaxel and topotecan;
and (b) the effects of intracellular acidification using EIPA, DIDS
and nigericin, on the cytotoxic potency of these drugs. Our results
show that the in vitro cytotoxic effects ofall three drugs for EMT6
and MGH-Ul cells are reduced at lowpHe, and that theireffects are
notenhanced by agents that induce intracellular acidification.
Our findings support the results of Jahde et al (1990), who
reported a decrease in cytotoxicity of mitoxantrone at low pHe.
Our data on mitoxantrone uptake show that there is a substantial
decrease in cellular accumulation at PHe 6.5 when compared with
PHe 7.4, which is consistent with the observed decrease in mitox-
antrone cytotoxicity at PHe 6.5. We observed a slight increase in
cellular accumulation of mitoxantrone when pH. modifiers EIPA
and DIDS were added. This effect is in contrast to the results of
a study of the effects of EIPA and DIDS on accumulation of
doxorubicin (Asaumi et al, 1995). One postulated mechanism for
decreased cytotoxicity ofmitoxantrone at low pHel is the protona-
tion status ofmitoxantrone, a weak base, at different pHe. At phys-
iological pHe (approximately 7.4), a larger proportion of drug
molecules would be uncharged, thus facilitating diffusion into
cells (Karuri et al, 1993). At low pHe (< 7.0), the proportion of
charged drug molecules would increase, resulting in decreased
drug diffusion into cells.
Paclitaxel is not fluorescent, and we did not measure the uptake
of this drug as a function ofpHe. Owing to its complex structure,
with both acidic and basic domains (Huizing et al, 1995), the total
charge of the paclitaxel molecule is unlikely to be a simple func-
tion ofpHel and it is therefore difficult to predict the effect ofpH
on drug uptake.
Topotecan, a topoisomerase I inhibitor, exists as a lactone
species, which is considered to be the bioactive form, and as a
carboxylate species, which represents the bioinactive form of the
drug (Potmesil, 1994). Hydrolysis of the lactone form to the
carboxylate species is very rapid under physiological conditions
(pH approximately 7, 37°C); Owing to its positive charge, the
Table Cell cycle distribution of EMT6 and MGH-U1 cells incubated atpH. 7.4 and 6.5 for 24 h, in the presence of EIPA, DIDS and/or nigericin
Percentage of cell population
EMT6 cells MGH-U1 cells
pH 7.4 pH 6.5 pH 7.4 pH 6.5
Sample GI S G2 GI S G2 G1 S G2 G1 S G2
Untreated cells 49.8 40.1 10.1 53.6 35.3 11.1 51.7 39.0 9.3 54.2 34.5 11.3
EIPA + DIDS 55.1 31.6 13.3 57.2 33.3 9.5 58.2 30.8 11.0 57.6 32.1 10.3
Nigericin 57.3 35.6 7.1 72.5 21.1 6.4 58.7 34.8 6.5 71.2 20.6 8.2
EIPA + DIDS + nigericin 71.5 22.3 6.2 80.1 13.3 5.7 79.4 14.3 6.3 79.9 11.4 8.7
Means are from three or four experiments.
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carboxylate form has reduced ability to diffuse passively into cells
and to interact with topoisomerase I (Hertzberg et al, 1989). At
low pH, hydrolysis to carboxylate is expected to be slower, with a
higher yield ofthe active drug form, and possibly higher cytotox-
icity in cell survival experiments. Under the experimental condi-
tions investigated, however, the uptake oftopotecan was enhanced
when PHe was at physiological values and intracellular acidifica-
tion was induced withnigericin. The increased uptake oftopotecan
in the presence ofnigericin, however, was not accompanied by an
equivalent increase in cytotoxicity. As nigericin is known to
increase the intracellular H+ concentration by facilitating K+/H+
exchange across the cell membrane, the bioactivity of topotecan
might be influenced by changes in cellular ions or by some other,
non-specific effects related to changes inpHi.
Intracellular acidification has been reported to inhibit cell-cycle
progression, leading to enrichment of cells in theG, phase of the
cell cycle (Musgrove et al, 1987). This effect was observed more
rapidly inEMT6 than in MGH-U1 cells (Table). Ithas been shown
that HeLa and SQ20B cells are most sensitive to paclitaxel and
docetaxel in S-phase and most resistant in G!GI phase
(Hennequin et al, 1996), thus providing aplausible explanation for
the approximately threefold decrease in cytotoxicity when pacli-
taxel was incubated with cells at low pHe with or without pHi
modifiers. This effect probably contributes also to resistance to
mitoxantrone (Sundman-Engberg et al, 1996) and topotecan, as
most cytostatic drugs are more active against cycling cells.
Our results suggest that low values of PHe might contribute to
resistance of solid tumours to mitoxantrone, paclitaxel and
topotecan. As values of PHe in certain areas of solid tumours are
known to be acidic, cells from these regions are more likely to
survive and repopulate a tumour after chemotherapy with agents
showing decreased cytotoxic potency under acidic conditions. Our
results do not suggest that manipulation ofthe pH gradient across
the cell membrane with EIPA, DIDS and/or nigericin will increase
the therapeutic effectiveness ofthese drugs.
ABBREVIATIONS
ELPA, 5-(N-ethyl-N-isopropyl) amiloride; DIDS, 4,4-diisothio-
cyanstilbene2,2-disulphonic acid; a-MEM, alpha-minimumessential
medium; BCECF-AM, 2',7'-bis-(2-carboxyethyl)-5-(and 6)-carboxy-
fluorescein acetomethylester;pHe,extracellularpH;pHl, intacellular
pH; Hepes, N-2-hydroxyethyl piperazine-N'-2-ethanesulphonic acid;
Bis-Tris, bis(2-hydroxyethyl)imino-tris(hydroxymethyl) methane.
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